肯尼亚基于GAIA标准的疫苗安全监测:现有国家和地方研究与项目系统可行性评估
研究评估肯尼亚三个现有数据收集系统用于孕产妇免疫接种主动监测的可行性,并评估最初为临床试验开发的GAIA病例定义在这些系统中的适用性。三个系统均能以不同GAIA确定性程度报告所选结局,ANCOV平台在收集和整理临床数据方面最为稳健;基于人群的研究可提供短期选项,国家电子数据系统具备长期能力建设基础。
要点
- 三个系统均能以不同GAIA确定性程度报告孕产妇免疫接种所选结局。
- ANCOV平台在收集和整理临床数据用于有效孕产妇药物警戒方面最为稳健。
- 基于人群的研究可为中低收入国家孕产妇疫苗药物警戒提供短期选项。
核心结论
- 基于人群的研究可为中国等中低收入国家实施孕产妇疫苗药物警戒提供短期选项,国家卫生电子数据系统具备长期能力建设的基础。
研究设计与样本
- 评估肯尼亚两个常规网络健康信息系统(Kenya EMR和DHIS-2)及一个基于网络的人群妊娠研究平台(ANCOV1)的可行性。
- 评估最初为临床试验开发的GAIA病例定义在孕产妇破伤风类毒素暴露、死产、低出生体重、小于胎龄儿、新生儿侵袭性血流感染(NIBSI)、早产和新生儿死亡中的适用性。
主要发现
- 三个系统均能以不同GAIA确定性程度报告所选结局。
- ANCOV平台在收集和整理临床数据用于有效孕产妇药物警戒方面最为稳健。
- 使用机构和地区汇总数据限制了DHIS-2在当前操作方式下用于药物警戒的实用性。
- Kenya EMR包含个体水平数据并满足有效药物警戒的关键考虑,但主要用于少量卫生机构的HIV护理和治疗记录,扩展至所有产前保健机构并链接母婴记录需要额外资源。
临床怎么用
- 作者认为,基于人群的研究可为中国等中低收入国家实施孕产妇疫苗药物警戒提供短期选项。
- 作者认为,国家卫生电子数据系统具备长期能力建设的基础,可提供这一关键服务并确保国家参与孕产妇疫苗安全国际研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Active surveillance systems for monitoring vaccine safety among pregnant women address some of the limitations of a current passive surveillance approach utilized in low- and middle-income countries (LMIC). However, few active surveillance systems in LMIC exist. Our study assessed the feasibility of utilizing three existing data collection systems in Kenya for active surveillance of maternal immunization and to assess the applicability of Global Alignment of Immunization Safety Assessment in pregnancy (GAIA) case definitions that were initially developed for clinical trials within these systems. METHODS: We assessed applicability of GAIA case definition for maternal Tetanus Toxoid exposure, stillbirth, low birth weight, small for gestational age, Neonatal Invasive Blood Stream Infection (NIBSI), prematurity and neonatal death in two routine web-based health information systems (Kenya EMR and DHIS-2), and a web-based population-based pregnancy research platform (ANCOV1) in Kenya. RESULTS: All three HIS were capable of reporting selected outcomes to varying degrees of GAIA certainty. The ANCOV platform was the most robust in collecting and collating clinical data for effective maternal pharmacovigilance. The utilization of facility- and district-aggregated data limits the usefulness of DHIS-2 in pharmacovigilance as currently operationalized. While the Kenya EMR contained individual level data and meets the key considerations for effective pharmacovigilance, it was used primarily for HIV care and treatment records in a small proportion of health facilities and would require additional resources to expand to all antenatal care facilities and to link maternal and infant records. DISCUSSION: Population-based research studies may offer a responsive short-term option for implementing maternal vaccine pharmacovigilance in LMICs. However, the foundation exists for long-term capacity building within the national health electronic data systems to provide this critical service as well as ensure participation of the country in international studies on maternal vaccine safety.
引用
- Izulla P, Wagai JN, Akelo V, et al. Vaccine safety surveillance in Kenya using GAIA standards: A feasibility assessment of existing national and subnational research and program systems. Vaccine. 2023. PMID: 37550143. doi:10.1016/j.vaccine.2023.07.063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。